ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: PO0165

Augmenter of Liver Regeneration Protects Kidney from Ischemia-Reperfusion Injury via Regulation of TLR4/MAPKs Signaling Pathway

Session Information

  • AKI Mechanisms - 1
    October 22, 2020 | Location: On-Demand
    Abstract Time: 10:00 AM - 12:00 PM

Category: Acute Kidney Injury

  • 101 AKI: Epidemiology, Risk Factors, and Prevention

Authors

  • Li, Ying, ChongqingTraditional Chinese Medicine Hospital, Chongqing, China
  • Xiong, Weijian, ChongqingTraditional Chinese Medicine Hospital, Chongqing, China
Background

Toll-like receptor 4 (TLR4) expressed within the ischemic kidney is a crucial mediator of innate activation and inflammation. The augmenter of liver regeneration (ALR) is an immunoregulator which is highly expressed in kidney upon induction of renal I/R injury. It has been shown that exogenous ALR can protect kidney against I/R injury. However, whether ALR’s protective effect results from its immune regulatory function has yet to be determined. In this study, we show that treating renal I/R induced-rats with recombinant human ALR (rhALR) protects them from kidney I/R.

Methods

Rats were randomized into 4 groups as follows: sham-operated group; I/R group; I/R+rhALR1 group; I/R+rhALR2 group. TLR4, neutrophils and macrophages were detected by immunochemistry. ERK, JNK, and p38 proteins were tested by WB. mRNA of HMGB-1, Biglycan, HAS1, HAS2 and HAS3 was detected by real-time PCR. The cytokines and chemokines were measured by ELISA.

Results

This result is corroborated by less tubular damage on rhALR treated rats than those on untreated rats. rhALR treated rats have significantly less apoptosis in tubular epithelial cells, less tubulointerstitial infiltration by neutrophils (24 h) and macrophages (72 h), as well as lower levels of inflammatory cytokines compared to the untreated control rats. Furthermore, rhALR downregulate mRNA expression of endogenous liagands for TLR4 and restrain activation of TLR4 and downstream signaling molecules (ERK, JNK and p38) on rats with renal I/R injury.

Conclusion

rhALR protects kidney from I/R injury by relieving the inflammatory responses via regulation of TLR4 signaling pathway.These results suggest that ALR might be used in the development of novel immune therapy for the renal IRI

rhALR protects kidney from I/R injury by regulation of TLR4 signaling pathway

Funding

  • Government Support - Non-U.S.